

## **Synonym**

Spike,S protein RBD,Spike glycoprotein Receptor-binding domain,S glycoprotein RBD,Spike protein RBD,COVID-19

### Source

SARS-CoV-2 S protein RBD, His Tag (SPD-C52H3) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1).

Predicted N-terminus: Arg 319

### **Molecular Characterization**

S protein RBD(Arg 319 - Lys 537) QHD43416.1

Poly-his

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 26.5 kDa. The protein migrates as 32-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

#### **Endotoxin**

Less than 1.0 EU per µg by the LAL method.

# **Purity**

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

## **Formulation**

Lyophilized from  $0.22 \mu m$  filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

## **Storage**


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


### **SDS-PAGE**



SARS-CoV-2 S protein RBD, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

# **Bioactivity-ELISA**


# **SEC-MALS**




The purity of SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) was more than 90% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.

Report






Immobilized Human ACE2, Fc Tag (Cat. No. <u>AC2-H5257</u>) at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. <u>SPD-C52H3</u>) with a linear range of 8-125 ng/mL (QC tested).




Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35)) with a linear range of 0.1-3 ng/mL (Routinely tested).

# **Bioactivity-SPR**




Human ACE2, Fc Tag (Cat. No. AC2-H5257) captured on CM5 chip via antihuman IgG Fc antibodies surface can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) with an affinity constant of 17 nM as determined in a SPR assay (Biacore T200) (Routinely tested).




Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1  $\mu$ g/mL (100  $\mu$ L/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-3 ng/mL (Routinely tested).



# **Bioactivity-BLI**



Loaded Human ACE2, Fc Tag (Cat. No. AC2-H5257) on Protein A Biosensor, can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) with an affinity constant of 34.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).



Loaded Biotinylated Human Neuropilin-1, His,Avitag (Cat. No. NR1-H82E3) on SA Biosensor, can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) with an affinity constant of 1.01  $\mu$ M as determined in BLI assay (ForteBio Octet Red96e)

## Background

It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

### References

- (1) Wan Y, et al. J Virol. 2020. pii: JVI.00127-20.
- (2) Benvenuto D, et al. J Med Virol. 2020.
- (3) Chang CY, et al. AMB Express. 2020. 10(1):20.

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.